In contrast, SIRT6 treatment prevented Ang II-mediated hypertension, pathological hypertrophy, myocardial fibrosis, dysfunction and injury by upregulation of ACE2 levels and suppression of the FKN signaling. This evidence concerns the gene CX3CL1 and hypertensive disorder.